HR+/HER2- BC: Selecting a CDK4/6 Inhibitor in the Frontline Setting
Taking into account all 3 available CDK4/6 inhibitors in HR+/HER2- breast cancer, experts consider how they’d select frontline therapy in this setting.
CKD4/6 Inhibition in HR+/HER2- BC: Trial Data With Palbociclib
Panelists share insight on clinical trial data behind use of palbociclib in the frontline setting of HR+/HER2- breast cancer.
CKD4/6 Inhibition in HR+/HER2- BC: Trial Data With Abemaciclib and Ribociclib
Focusing on the frontline setting of HR+/HER2- breast cancer, panelists discuss clinical trial data with abemaciclib and ribociclib, respectively.
Frontline Treatment Strategies for HR+/HER2- Breast Cancer
Expert perspectives on the evolving treatment paradigm for patients receiving frontline therapy for HR+/HER2- breast cancer.
Role of ctDNA in the Neoadjuvant Setting of Breast Cancer
Expert perspectives on the value of circulating tumor DNA in the neoadjuvant setting of breast cancer management.
Applications of ctDNA Assessment in Metastatic Breast Cancer and Relapse
Aditya Bardia, MD, MPH, shares insight on how circulating tumor DNA is used in metastatic breast cancer and relapse detection.
Applications of ctDNA Assessment in Early Breast Cancer
Barry Rosen, MD, provides an overview of circulating tumor DNA’s role in early stage breast cancer detection and management.
An Overview of Minimal Residual Disease (MRD) Testing
Expert oncologist Aditya Bardia, MD, MPH, provides a broad overview of minimal residual disease testing across a number of tumor types and clinical settings.
Dr. Bardia on the Efficacy Results of the EMERALD Trial in ER+/HER2- Breast Cancer
Aditya Bardia, MD, MPH, discusses the efficacy results of the phase 3 EMERALD trial in estrogen receptor–positive, HER2-negative metastatic breast cancer.
Advances Treating HR+ Metastatic Breast Cancer
Various breast oncologists discuss the potential effect of treatment advances in hormone receptor-positive metastatic breast cancer.
Novel Therapies Under Investigation for HR+ MBC
An overview of key presentations from ESMO 2021 that continues studying the potential effect of novel-based treatment options for use in hormone receptor-positive metastatic breast cancer.
HR+ MBC: Genomic Testing and Treatment Guidance
A discussion on the current utilization of molecular testing in patients with HR-positive metastatic breast cancer, and recommendations for conducting liquid and tissue biopsies to help inform treatment decisions.
HR+ MBC: Ribociclib and Patient Quality of Life
Considerations for treating HR+ metastatic breast cancer with ribociclib plus endocrine therapy based on quality-of-life metrics demonstrated by a recent ESMO 2021 presentation.
Dr. Bardia on the Rationale for the AMEERA-5 Trial in ER+/HER2- Breast Cancer
Aditya Bardia, MD, MPH, discusses the rationale for the ongoing phase 3 AMEERA-5 trial in estrogen receptor–positive, HER2-negative breast cancer.
Dr. Bardia on Ongoing Research With Amcenestrant and Palbociclib in ER+/HER2- Advanced Breast Cancer
Aditya Bardia, MD, MPH, discusses ongoing research with amcenestrant and palbociclib in estrogen receptor–positive, HER2-negative advanced breast cancer.
Dr. Bardia on Efficacy With Atezolizumab Combos in Metastatic TNBC
Aditya Bardia, MD, MPH, discusses efficacy with atezolizumab combinations in patients with metastatic triple-negative breast cancer.
Dr Cook on Real-World Data With Bridging Therapy and Axi-Cel in Relapsed/Refractory LBCL
Dr Goy on Outcomes From An Expanded Access Study of Brexu-Cel in Relapsed/Refractory MCL
Ide-Cel Provides HRQOL Benefits Over Standard Regimens in R/R Multiple Myeloma
Bridging Therapy Prior to Axi-Cel Produces Favorable Real-World Outcomes in R/R LBCL
2 Clarke Drive Cranbury, NJ 08512